• 2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%*

• 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77

• Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA

• Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint by $2 billion dollars to 5.4% and full year EPS guidance by $0.25 to $10.85. Adjusted operational EPS increased to $10.68 at the midpoint.
July 16, 2025
Share

see & read more on
https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2025-results-raises-2025-outlook